IL235390A0 - A preparation based on phosphatidylcholine to increase the bioavailability of methylnaltrexone - Google Patents
A preparation based on phosphatidylcholine to increase the bioavailability of methylnaltrexoneInfo
- Publication number
- IL235390A0 IL235390A0 IL235390A IL23539014A IL235390A0 IL 235390 A0 IL235390 A0 IL 235390A0 IL 235390 A IL235390 A IL 235390A IL 23539014 A IL23539014 A IL 23539014A IL 235390 A0 IL235390 A0 IL 235390A0
- Authority
- IL
- Israel
- Prior art keywords
- phosphatidylcholine
- bioavailability
- increases
- based formulation
- oral methylnaltrexone
- Prior art date
Links
- JVLBPIPGETUEET-WIXLDOGYSA-O (3r,4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one Chemical compound C([N@+]1(C)[C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)C1CC1 JVLBPIPGETUEET-WIXLDOGYSA-O 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 229960002921 methylnaltrexone Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261642837P | 2012-05-04 | 2012-05-04 | |
| PCT/US2013/031078 WO2013165577A1 (en) | 2012-05-04 | 2013-03-13 | Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL235390A0 true IL235390A0 (en) | 2014-12-31 |
Family
ID=49514721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL235390A IL235390A0 (en) | 2012-05-04 | 2014-10-29 | A preparation based on phosphatidylcholine to increase the bioavailability of methylnaltrexone |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150190523A1 (enExample) |
| EP (1) | EP2854537A4 (enExample) |
| JP (1) | JP2015515982A (enExample) |
| KR (1) | KR20150006877A (enExample) |
| CN (1) | CN104470361A (enExample) |
| AU (1) | AU2013257211A1 (enExample) |
| BR (1) | BR112014027496A2 (enExample) |
| CA (1) | CA2872400A1 (enExample) |
| HK (1) | HK1207940A1 (enExample) |
| IL (1) | IL235390A0 (enExample) |
| IN (1) | IN2014DN09359A (enExample) |
| MX (1) | MX2014013425A (enExample) |
| WO (1) | WO2013165577A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3206491B1 (en) * | 2014-10-17 | 2019-11-27 | Salix Pharmaceuticals, Inc. | Use of methylnaltrexone to attenuate tumor progression |
| WO2021224138A1 (en) * | 2020-05-02 | 2021-11-11 | Bausch Health Ireland Limited | Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7846478B2 (en) * | 2002-01-31 | 2010-12-07 | Henkel Ag & Co. Kgaa | Bioadhesive composition |
| CN101432011A (zh) * | 2006-02-27 | 2009-05-13 | 亚历山大·米哈洛 | 通过诱导逆适应调节神经递质系统的方法 |
| EP2061440A2 (en) * | 2007-04-04 | 2009-05-27 | Sigmoid Pharma Limited | A pharmaceutical composition of tacrolimus |
| EP2306829B1 (en) * | 2008-07-01 | 2017-01-04 | University of Chicago | Particles containing a peripheral opioid receptor antagonist |
| WO2011083304A1 (en) * | 2010-01-05 | 2011-07-14 | Shire Llc | Prodrugs of opioids and uses thereof |
| US20120053130A1 (en) * | 2010-08-30 | 2012-03-01 | Bristol-Myers Squibb Company | Composition for enhancing absorption of a drug and method |
-
2013
- 2013-03-13 MX MX2014013425A patent/MX2014013425A/es unknown
- 2013-03-13 BR BR112014027496A patent/BR112014027496A2/pt not_active IP Right Cessation
- 2013-03-13 JP JP2015510266A patent/JP2015515982A/ja not_active Withdrawn
- 2013-03-13 EP EP13785315.6A patent/EP2854537A4/en not_active Withdrawn
- 2013-03-13 AU AU2013257211A patent/AU2013257211A1/en not_active Abandoned
- 2013-03-13 CA CA2872400A patent/CA2872400A1/en not_active Abandoned
- 2013-03-13 US US14/398,914 patent/US20150190523A1/en not_active Abandoned
- 2013-03-13 HK HK15108676.7A patent/HK1207940A1/xx unknown
- 2013-03-13 CN CN201380028597.4A patent/CN104470361A/zh active Pending
- 2013-03-13 WO PCT/US2013/031078 patent/WO2013165577A1/en not_active Ceased
- 2013-03-13 KR KR20147034096A patent/KR20150006877A/ko not_active Withdrawn
- 2013-03-13 IN IN9359DEN2014 patent/IN2014DN09359A/en unknown
-
2014
- 2014-10-29 IL IL235390A patent/IL235390A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150006877A (ko) | 2015-01-19 |
| AU2013257211A1 (en) | 2014-11-27 |
| EP2854537A4 (en) | 2016-04-06 |
| CN104470361A (zh) | 2015-03-25 |
| HK1207940A1 (en) | 2016-02-19 |
| CA2872400A1 (en) | 2013-11-07 |
| MX2014013425A (es) | 2015-08-14 |
| WO2013165577A1 (en) | 2013-11-07 |
| EP2854537A1 (en) | 2015-04-08 |
| IN2014DN09359A (enExample) | 2015-07-17 |
| BR112014027496A2 (pt) | 2018-05-15 |
| US20150190523A1 (en) | 2015-07-09 |
| JP2015515982A (ja) | 2015-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201406799XA (en) | A delayed release drug formulation | |
| ZA201409020B (en) | Pharmaceutical formulation | |
| GB201216385D0 (en) | A pharmaceutical composition | |
| AU345131S (en) | A cup | |
| ZA201405925B (en) | Pharmaceutical formulation having improved stability | |
| SG11201406097SA (en) | Capsule formulation | |
| ZA201407675B (en) | A delayed release drug formulation | |
| ZA201408114B (en) | Oral formulation | |
| PH32012000576S1 (en) | Design feature for an oral dosage form | |
| PH32012000578S1 (en) | Design feature for an oral dosage form | |
| PH32012000577S1 (en) | Design feature for an oral dosage form | |
| PH32012000575S1 (en) | Design feature for an oral dosage form | |
| GB201221367D0 (en) | A pharmaceutical composition |